2. Anti-infection
  3. Influenza Virus Arenavirus
  4. VV261

VV261 is an orally active prodrug of 4'-fluorouridine. VV261 inhibits viral RNA-dependent RNA polymerase. VV261 exhibits antiviral activity against CCHFV, SFTSV and LCMV. VV261 can be used in research related to viral infections.

For research use only. We do not sell to patients.

VV261

VV261 Chemical Structure

CAS No. : 3003864-86-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

VV261 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

VV261 is an orally active prodrug of 4'-fluorouridine. VV261 inhibits viral RNA-dependent RNA polymerase. VV261 exhibits antiviral activity against CCHFV, SFTSV and LCMV. VV261 can be used in research related to viral infections[1][2].

In Vitro

VV261 (up to 200 µM) potently inhibits CCHFV infection in HUVEC, with an EC50 of 2.72 µM. It exhibits extremely low cytotoxicity, with a selectivity index greater than 73.53[1].
VV261 (2-50 µM) inhibits the activity of CCHFV RdRp in BSR-T7/5 cells in a dose-dependent manner[1].
VV261 (48 h) potently inhibits SFTSV replication in Vero-ATCC cells, with an EC50 of 0.89 μM[2].
VV261 (48 h) potently inhibits LCMV replication in A549 cells, with an EC50 of 0.15 μM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VV261 Related Antibodies

Real Time qPCR[2]

Cell Line: A549 cells
Concentration: /
Incubation Time: 48 h
Result: Inhibited LCMV replication with an EC50 of 0.15 μM.
Showed no measurable cytotoxicity at concentrations up to 100 μM, resulting in a selectivity index of >667.
In Vivo

VV261 (1-10 mg/kg; p.o.; once daily; for 6 consecutive days) inhibits viral replication in a lethal CCHFV mouse model[1].
VV261 (2.5-10 mg/kg; p.o.; once daily; for 7 consecutive days) exhibits dose-dependent anti-SFTSV efficacy in IFNAR1tm1Agt mice[2].
VV261 (1-5 mg/kg; p.o.; once daily; for 7 consecutive days) exhibits dose-dependent anti-LCMV efficacy in C57BL/6-Prf1tm1Sdz/J mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A129 mice (IFNα/β receptor-deficient) (10-week-old male, intraperitoneally challenged with 10 TCID50 CCHFV)[1]
Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg
Administration: p.o.; once daily; 6 days
Result: Showed no significant weight loss, 100% survival through the observation period, and nearly undetectable viral loads in liver and spleen tissue (5 mg/kg and 10 mg/kg doses).
Exhibited delayed weight loss and extended survival compared to vehicle controls, but did not achieve full protection, and had ineffective viral load suppression in liver and spleen tissue (1 mg/kg dose).
Remarkably alleviated liver tissue damage (reduced hepatocellular necrosis and lymphocyte filtration) and preserved splenic structure (5 mg/kg and 10 mg/kg doses).
Animal Model: IFNAR1tm1Agt mice (6-8 weeks old; intraperitoneal infection with 1000 PFU SFTSV)[2]
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: p.o.; once daily; 7 days
Result: Achieved 16.7% survival rate at 2.5 mg/kg, and 100% survival rate at 5 mg/kg and 10 mg/kg.
Caused initial weight loss with recovery by Day 6 at 2.5 mg/kg; prevented weight loss at 5 mg/kg and 10 mg/kg.
Restored near-normal platelet counts and lymphocyte percentages in a dose-dependent manner.
Reduced viral RNA copies in a dose-dependent manner.
Led to significant reduction in infectious virus titers compared to vehicle at 2.5 mg/kg; reduced titers below the limit of detection in multiple organs at 5 mg/kg and 10 mg/kg on Day 2 post-infection.
Improved splenic tissue lesions at all doses, with normal splenic tissue structure, clear red/white pulp boundaries, dense and organized lymphocytes in white pulp, and no observable necrosis or significant inflammatory cell infiltration.
Animal Model: C57BL/6-Prf1tm1Sdz/J mice (intraperitoneal infection with 20,000 PFU LCMV)[2]
Dosage: 1 mg/kg; 2.5 mg/kg; 5 mg/kg
Administration: p.o.; once daily; 7 days
Result: Achieved 100% survival rate at all tested doses.
Prevented weight loss at all tested doses.
Restored near-normal platelet counts and lymphocyte percentages in all treated groups.
Reduced viral RNA copies in spleen, liver, lung, and kidney in a dose-dependent manner, with efficacy outperforming the reference drug group at all doses on Day 5 post-infection.
Reduced infectious virus titers in spleen, liver, lung, and kidney in a dose-dependent manner; reduced titers below the limit of detection at 2.5 mg/kg and 5 mg/kg in multiple organs, outperforming the reference drug group on Day 5 post-infection.
Significantly improved splenic tissue lesions at all doses, with largely normal splenic structure, clear red/white pulp boundaries, no evident necrosis, and no significant inflammatory cell infiltration.
Molecular Weight

607.58

Formula

C28H34FN3O11
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

O=C(C1=CC=CN=C1)OCN2C(N(C=CC2=O)[C@@H]3O[C@@](COC(C(C)C)=O)(F)[C@@H](OC(C(C)C)=O)[C@H]3OC(C(C)C)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (164.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6459 mL 8.2294 mL 16.4587 mL
5 mM 0.3292 mL 1.6459 mL 3.2917 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6459 mL 8.2294 mL 16.4587 mL 41.1468 mL
5 mM 0.3292 mL 1.6459 mL 3.2917 mL 8.2294 mL
10 mM 0.1646 mL 0.8229 mL 1.6459 mL 4.1147 mL
15 mM 0.1097 mL 0.5486 mL 1.0972 mL 2.7431 mL
20 mM 0.0823 mL 0.4115 mL 0.8229 mL 2.0573 mL
25 mM 0.0658 mL 0.3292 mL 0.6583 mL 1.6459 mL
30 mM 0.0549 mL 0.2743 mL 0.5486 mL 1.3716 mL
40 mM 0.0411 mL 0.2057 mL 0.4115 mL 1.0287 mL
50 mM 0.0329 mL 0.1646 mL 0.3292 mL 0.8229 mL
60 mM 0.0274 mL 0.1372 mL 0.2743 mL 0.6858 mL
80 mM 0.0206 mL 0.1029 mL 0.2057 mL 0.5143 mL
100 mM 0.0165 mL 0.0823 mL 0.1646 mL 0.4115 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

VV261 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

VV2613003864-86-3VV 261VV-261Influenza VirusArenavirushuman endothelial cellsVero-ATCC cellsBSR-T7/5 cellsRNA-dependent RNA polymeraselymphocytic choriomeningitis virusHUVECsA129 miceA549 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
VV261
Cat. No.:
HY-172918
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.